| Presentation preference | Oral presentation |
| Title | Fluocinolone acetonide insert for uveitis: efficacy and experience from a tertiary center |
| Purpose | Macular oedema (CME) is one of the main causes of visual deterioration in uveitis. Nowadays, good visual acuity (VA) can often be maintained with appropriate treatment as steroid depot systems. |
| Methods | The aim of our study was to investigate the efficacy of fluocinolone acetonide inserts (FAc, 0.19mg) in the treatment of non-infectious uveitis. A total of 90 injections were followed. Three subgroups were identified. Group A (follow-up of at least 24 months), group B (follow-up of max. 12 months) and group C (intervention, e.g. dexamethasone insert within first 12 months). In our analysis central retinal thickness (CRT), (VA) and intraocular pressure (IOP) were recorded as outcome measures. |
| Results | The spectrum of uveitis was distributed as: anterior uveitis in group A 5.8%/ group B 9.1%/ group C 16.7%, intermediate uveitis 47%/22.73%/33.3%, posterior uveitis 35.3%/15.9%/22.2%, Panuveitis 5.9%/36.4%/16.7% and other 5.8%/15.91%/11.1%. Distribution of previous dexamethasone inserts: 4.0±4.7/5.3±3.8/9.0±4.7 (M±SD). FAc therapy significantly reduced CRT in all 3 groups (p<0.01) within 1 month of starting therapy. Subsequently, a significant increase in VA after 1 month was observed in groups A and B. However, even after 3 months, there was no significant increase of VA in group C. This trend was confirmed in the long-term follow-up for up to 36 months. An increase in IOP at 6 months was observed in all 3 groups. This increase was reversible in all eyes with glaucoma medication. |
| Conclusion | Intravitreal administration of the FAc resulted in a reduction of CME with an improvement in VA. We were able to identify a group of non-responders. An initially rising IOP could be treated conservatively and well controlled. |
| Conflict of interest | No |
Authors 1
| Last name | PLEYER |
| Initials of first name(s) | U |
| Department | Ophthalmology, Charité University Medicine Berlin |
| City | Berlin |
| Country | Germany |
Authors 2
| Last name | Knecht |
| Initials of first name(s) | V A |
| Department | Ophthalmology, Charité University Medicine Berlin |
| City | Berlin |
| Country | Germany |
Authors 3
| Last name | Pohlmann |
| Initials of first name(s) | D |
| Department | Ophthalmology, Charité University Medicine Berlin |
| City | Berlin |
| Country | Germany |
Authors 4
| Last name | Rübsam |
| Initials of first name(s) | A |
| Department | Ophthalmology, Charité University Medicine Berlin |
| City | Berlin |
| Country | Germany |
Authors 5
| Last name | Madrossa |
| Initials of first name(s) | D |
| Department | Ophthalmology, Charité University Medicine Berlin |
| City | Berlin |
| Country | Germany |
Authors 6
| Last name | Rau |
| Initials of first name(s) | S |
| Department | Ophthalmology, Charité University Medicine Berlin |
| City | Berlin |
| Country | Germany |
Authors 7
| Last name | Lussac |
| Initials of first name(s) | V |
| Department | Ophthalmology, Charité University Medicine Berlin |
| City | Berlin |
| Country | Germany |
